Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2011057027 - MÉTHODE DE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE AVEC DES PEPTIDES DE TYPE STRESSCOPINE

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS:

What is claimed is:

1 . A method for treating heart failure in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of stresscopin-like peptide in a dose that does not exceed a stresscopin relative concentration of 7.2 ng/mL in the subject for a continuous period of more than about 15 minutes.

2. The method of claim 1 , wherein the dosage that does not exceed a stresscopin relative concentration of 5.5 ng/mL in the subject for continuous period or more than about 10 minutes.

3. The method of claim 1 , wherein the dosage that does not exceed a stresscopin relative concentration of 4.7 ng/mL in the subject for continuous period or more than about 10 minutes.

4. The method of claim 1 , wherein the plasma concentration of said subject is substantially maintained between a stresscopin-relative concentration of about 0.1 ng/mL to about 7.2 ng/mL during the treatment.

5. The method of claim 4, wherein the plasma concentration of said subject is substantially maintained between a stresscopin-relative concentration of about 0.1 ng/mL to about 5.5 ng/mL during the treatment.

6. The method of claim 4, wherein the plasma concentration of said subject is substantially maintained between a stresscopin-relative concentration of about 0.1 ng/mL to about 4.7 ng/mL during the treatment.

7. The method of claim 1 , wherein said stresscopin-like peptide is administered over a period of at least about 30 minutes.

8. The method of claim 1 , wherein said dose is administered via a parenteral route.

9. The method of claim 8, wherein said parenteral route is selected from the group consisting of intravenous administration, subcutaneous administration, and intramuscular administration.

10. A method for treating heart failure in a subject in need thereof, said method comprising intravenously administering a stresscopin-like peptide at a stresscopin-relative dosing rate of between about 0.2 ng/kg/min to about 52 ng/kg/min over a time period of at least about 30 minutes.

1 1 . The method of claim 10, wherein said stresscopin-like peptide is intravenously administered at a stresscopin-relative dosing rate of between about 0.2 ng/kg/min to about 36 ng/kg/min over a time period of at least about 30 minutes.

12. The method of claim 10, wherein said stresscopin-like peptide is intravenously administered at a stresscopin-relative dosing rate of between about 0.4 ng/kg/min to about 18 ng/kg/min over a time period of at least about 30 minutes.

13. The method of claim 10, wherein said stresscopin-like peptide is subcutaneously administered at a stresscopin-relative bolus dose of between 0.002 μg/kg to about 0.2 μg/kg.

14. The method of claim 10, wherein said stresscopin-like peptide comprises the amino acid sequence of SEQ ID NO. 1 or 29, said amino acid sequence of SEQ ID NO. 1 or 29 optionally conjugated at position 28 with


wherein R is the stresscopin-like peptide having the amino acid sequence of SEQ ID NO. 1 or 29, and S is the sulfur atom of the cysteine thiol group at position 28.

15. The method of claim 10, wherein said stresscopin-like peptide is intravenously administered at a dosing rate of between about 0.2 ng/kg/min to about 52 ng/kg/min over a time period of at least about 30 minutes.

16. The method of claim 14, wherein said stresscopin-like peptide is subcutaneously administered at a bolus dose of between 0.002 μg/kg to about 0.2 μg/kg.

17. The method of claim 1 , wherein said dose comprises a peptide having the amino acid sequence of SEQ ID NO. 19, and S is the sulfur atom of the cysteine thiol group at position 18.

18. The method of claim 17, wherein said dose is intravenously administered at a dosing rate of between about 6 ng/kg/min to about 1700 ng/kg/min over a time period of at least about 30 minutes.

19. The method of claim 17, wherein said dose is subcutaneously administered at a bolus dose of between 0.01 μg/kg to about 1 μg/kg.

20. The method of claim 1 , wherein said stresscopin-like peptide comprises polyethylene glycol (PEG) to a linker, wherein said linker is attached to the stresscopin-like peptide and the PEG weighs no more than about 80 kDa.

21 . The method of claim 20, wherein said stresscopin-like peptide comprises a conjugate selected from


and


wherein n is an integer of about 460, R is a peptide having the amino acid sequence of SEQ ID NO. 29, and S is the sulfur atom of the cysteine thiol group at position 28.

22. The method of claim 21 , wherein said dose is intravenously administered at a dosing rate of between about 20 ng/kg/min to about 5200 ng/kg/min over a time period of at least about 30 minutes.

23. The method of claim 21 , wherein said dose is subcutaneously administered at a bolus dose of between 0.9 μg/kg to about 100 μg/kg.

24. The method of claim 1 , wherein said stresscopin-like peptide is at least about 90% homologous to the peptide of SEQ ID NO:1 .

25. The method of claim 1 , wherein said stresscopin-like peptide is at least about 90% identical to the peptide of SEQ ID NO:1 .